Immunothérapie fondée sur les cellules natural killer: Implication des cellules dendritiques

Translated title of the contribution: NK cell-based immunotherapy: New prospects and involvement of dendritic cells

Christophe Borg, Julien Taieb, Magali Terme, Kuji Maruyama, Caroline Flament, Eric Angevin, Laurence Zitvogel

    Research output: Contribution to journalReview articlepeer-review

    8 Citations (Scopus)

    Abstract

    Dendritic cells (DC) were initially described as antigen presenting cells able to prime naive T cells. In fact, dendritic cells are also able to activate natural killer (NK) cells. The crosstalk between DC and NK is now regarded as a main stage in the initiation of innate and adaptative immune responses. Moreover, DC mediated-NK cell activation is particularly efficient since DC promote both effector functions and survival or proliferation of NK cells. Furthermore, recent publications in the field of NK cell biology underscore a role for NK cells in anti-tumor effects. NK cell-based immunotherapy should be reconsidered. Here, we will report how pioneering immunotherapy trials based on natural cytotoxicity and progress in NK cell biology can promote NK cells in anti-tumor immune responses. Then, we will discuss the biological features of the DC/NK crosstalk and its implementations in immunotherapy protocols.

    Translated title of the contributionNK cell-based immunotherapy: New prospects and involvement of dendritic cells
    Original languageFrench
    Pages (from-to)699-705
    Number of pages7
    JournalBulletin du Cancer
    Volume90
    Issue number8-9
    Publication statusPublished - 1 Aug 2003

    Cite this